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Summary
Qa-2 is a nonclassical class I molecule encoded by the Q7 gene within the mouse major
histocompatibility complex (MHC). Results from previous experiments on Qa-2, and on a chimeric
Ld molecule (LQ3) in which the 0 domain is encoded by Q7b, suggested that the a3 domain
of Qa-2 does not carry out the functions typical ofthe 0 domains in other classical and nonclassical
class I antigens. Class I molecules that contain the Qa-2 tx3 domain are poorly recognized by
primary cytotoxic T lymphocytes (CTLs), and do not function normally in either positive or
negative selection in vivo. By employing a cell-cell adhesion assay we demonstrate directly that
the Qa-2 0 domain in the context of the LQ3 hybrid molecule cannot bind to human CD8,
although other mouse class 10 domains bind efficiently. In addition, CD8-dependent CTL-
mediated lysis of target cells, in a system which requires mouse CD8-class I a3 domain interactions,
is deficient in cells that express the Qa-2 0 domain. When combined with our earlier work
on LQ3 transgenic mice, these results provide additional molecular support for the hypothesis
that interaction with CD8 is required for both positive and negative selection ofclass I restricted
T cells in the thymus. As the Qa-2 0 domain sequence does not differ from the previously
defined minimal CD8 binding sequence of other class I molecules, these results also suggest
that additional amino acidsin the 0 domain must be critical for CD8 binding and CTL activation.
T
he mouse genome contains a number of expressed non-
classical class I, class Ib, or medial class I genes encoded
within the Qa, Tla, and Hmt subregions of the MHC
(reviewed in reference 1). Although their function(s) remain
speculative, increasing evidence suggests that some of these
molecules are capable ofpresenting peptide antigens to CTLs.
Nonclassical class I molecules have a significant degree of se-
quence similaritywith classical classI molecules such as H-2K
and H-2D, and they are also coexpressed with 02-
microglobulin (1). Recent evidence indicates that the thymus
leukemia antigen (TLA),' a mouse class Ib molecule, and
HLA-G, a human nonclassical class I molecule, can bind effec-
tively to CD8 (2, 3). Furthermore, the Mta and Qa-1 class
Ib molecules have been shown to require a functional pep-
1 Abbreviations used in this paper. CHO, Chinese hamster ovary; LQ3, a chi-
meric class I molecule in which the tx3 domain is encoded by the Q7b
gene and the remainder by the Ld gene; TLA, thymus leukemia antigen.
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tide transporter for their surface expression and recognition
by T cells (4), and T lymphocytes that recognize defined pep-
tide antigens in the context of these two molecules have been
described (5, 6).
The Q7b gene encodes a Qa-2 molecule in C57BL/10
mice (7). The results from several experiments suggest that
the a3 domain of this molecule may be functionally different
from other class 10 domains. Alloreactive, Qa-2 specific
CTLs can only be detected in mice that have been previously
primed in vivo (8, 9). Similar results were obtained using
a chimeric Ld molecule, LQ3, in which the 0 domain is en-
coded by Q7b and the remainder by the Ld gene (10). Pri-
mary, CD8-dependent, alloreactive or virus-specific CTLs
could lyse Ld transfectant cell lines but not LQ3 transfected
targets. Despite this, secondary CD8-independent CTLs could
lyse LQ3 transfected targets (10). The chimeric LQ3 molecule
was shown to bind a viral peptide that also binds to Ld and,
as is seen with Ld, surface expression of LQ3 was increased
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that the Ld peptide binding site in LQ3 is unaffected,
localizing the defect in this chimeric molecule to the a3
domain.
Class I molecules rely on their a3 domains for intercel-
lular interaction with the T cell coreceptor molecule CD8.
This interaction canbe demonstrated directly in bindingassays
using lymphoid cell lines that overexpress transfected class
Igenes (11) . Previous assay results have shownthat all mouse
class I and classIb MHCantigens so farexamined are capable
of binding human CD8a/a homodimers (2, 11, 12). Using
this assay, a minimal CD8 binding site has been located on
an external facing loop ofthe human class 10 domain (12).
Given theCD8-independent nature ofboth Qa-2-specific and
LQ3-specific CTLs, it is reasonable to hypothesize that the
Qa-2 0domain does notinteract with CD8. Although most
of theearlier data citedaboveis consistent with this interpre-
tation, there aretwo pieces of evidence that are inconsistent.
First, it was possible in the previous studies to obtain sec-
ondary, Ld-specific T cell clones that were not inhibitable
by anti-CD8 mAbs, but which also could not lyse LQ3-
transfected targets (10). This suggests that therecouldbe some
other defect in the LQ3, or Qa-2 a3 domain besides the in-
ability to bind CD8, although the mAb blocking studies may
not detect all CD8-dependent T lymphocytes. Second, there
are no sequence differences in the defined CD8 binding site
between the Qa-2 0domain and the 0 domains of class
I molecules that are known to interact with CD8. There-
fore, to determinedirectly if theQa-2 0domain canmediate
binding to human CD8, a cell-cell adhesion assay was em-
ployed. In addition, the Qa-2 a3 domain was tested in afunc-
tional assay: CTL-mediated cytolysis of cell targets that re-
lies only on the ability of mouse CD8a/(3 heterodimers to
interact with class 10 domain was assessed.
Materials and Methods
Gene Constructs and Transfectants.
￿
TheTLA expression construct
pHOAprT18d and the chimeric Ld/TLA molecule expression
construct pH,6AprLT18d have been previously described (2).
pH/6AprT18d encodes a full-length T18d cDNA while pHOApr-
LT18dencodes a genomic sequence containing the H-2Ld a1 and
a2 domains coupled to a T18d genomic sequence encoding the a3,
transmembrane, and cytoplasmic domains. Both class I gene con-
structs areexpressedunder thecontrol of the human 0-actin gene
promoter (13). This promoter gives higher levels of expression of
mouse class I genes in CIR B cells than do either theH-2D1 or
H-2Ld promoters (2; data not shown). A chimeric gene (LQ3) en-
coding the H-2Ld al, a2, transmembrane, and cytoplasmic do-
mains along with an a3 domain supplied by Q76, expressed under
the control of the ,6-actin gene promoter, was created as follows:
A 2.9-kb BamHI fragment containing the Q76 0 domain fused
to Ld transmembrane and cytoplasmic domains was excised from
thepreviously reported expression vector LLQL23 (10). This frag-
ment was cloned into the BamHI polyfnker sites of the cloning
vector p34E (14). The fragment was then excised from the resul-
tant constructwith Xbal digestion and ligated into placein XbaI
digested pHOAprLT18d. Xbal digestion removes all T18d gene se-




striction enzyme digestion and agarose gel electrophoresis of the
resultant plasmid clones. This new construct was designated
pH,6AprLLQL.
Gene transfer of 20 Ag of each expression vector along with
10 Ag ofthe drug selection plasmidpSV2neo (15) into humanCIR
Blymphoma cells wasaccomplished by standard coelectroporation
procedures (GeneTransfector 300; BTX Inc., SanDiego, CA; [2]).
G418 (GIBCO BRL, Gaithersburg, MD) selection at 600 tag/ml
active drug began 48 h after electroporation, and stable transfec-
tants were chosen 3-4wk later as previously described(2). A CIR
Bcell transfectant expressing thehumanclass I transplantation an-
tigen HLA-A2.1 wasobtained as akind gift from Dr. D. Littman,
University of California at San Francisco, San Francisco, CA (11).
Detection ofClass A MHC Antigen Expression.
￿
Cell surfacemAb
staining of CIR transfectants was performed as described previ-
ously (16). The primary mAbs used included the antiTLA mAb
TL.m4 (17), which was protein-A column purified and used at a
1:200 dilution. The TL.m4 mAb was kindly provided by Dr. S.
Kimura andDr. E. Boyse, Sloan-KetteringMemorial Cancer Insti-
tute, New York. The anti-L' mAb 30-5-7 (18) was obtained as
tumorascites fluid andused at a 1:25dilution.It waskindly provided
by Dr. M. McMillan, University of Southern California School
of Medicine, Los Angeles, CA. The anti-human R2-microglobulin
mAb BBM.1 (19) was used as an undilutedtissue culture superna-
tant and waskindly providedby Dr.L. Sherman, Scripps Research
Institute, La Jolla, CA. The secondary staining reagent employed
was a1:100 dilution ofphycoerythrin-conjugated goat anti-mouse
IgG(CALTAGLabs, South SanFrancisco, CA) that detectsallthree
mAbs. Afterstaining andwashing, cells were analyzed in propidium
iodide using a FACScan® instrument (Becton Dickinson andCo.,
Palo Alto, CA, and University of California at Los Angeles Flow
Cytometry Core Facility, Los Angeles, CA).
Cell-Cell Adhesion Assay.
￿
This method has been described in
detail elsewhere(11, 12). Briefly, 3dbefore theassay adherent human
CD8a(+)or mock-transfected Chinesehamsterovary(CHO)cells
at 5 x 1(}3-104 cells per well were placed in 96-well flat-bottom
microtiter plates. Optimalconfluent monolayers, as judged by vi-
sual inspection, were used on the dayof assay. Parent and transfec-
tant CIR B cell lines were incubated for 2 h in [3sS]methionine
(>12.5 mCi/106 cells, >600 Ci/mmol; Amersham Corporation,
Arlington Heights, IL) in 1x MEMwithoutL-methionine (Flow
Laboratories Inc., McLean, VA). The labeledcells were then added
to the plate wells, centrifuged to initiate contact, and incubated
at 37°C for 1 h with gentle shaking. After incubation, the wells
were washed 10-12 times each with assay buffer (1 x PBS, pH 7.4,
10% FCS, and 0.01% NaN3) and the remaining bound cells were
solubilized in 1% Triton X-100 for scintillation counting.
Cell Lysis Assay.
￿
Anti-Kb alloantigenic CTL clone lines C30
andC35were obtained from Dr. M. Mescher(Department ofLab-
oratory Medicine and Pathology, University of Minnesota, Min-
neapolis, MN). These clones were grownin HEPES-supplemented
RPMI 1640 with 10% FCS and were stimulated once each week
with irradiated C57B1/6splenocytes and twiceeach week with rIIT2.
The CTL clones were activated by preincubation with either 10
hg/ml of fluid-phase mAb 2C11 (anti-CD3, both clones) or 10
hg/mlofmAbF23.1(antiV,68, cloneC35 only)at room temper-
aturefor10 min. mAb-preincubated or untreatedTcellclones were
then added to 96-well "V" bottom plates containing 104 "Cr-
loaded CIR transfectant cells in various effector to target ratios.
Assay plates were spun at 160g for 3 min to initiate effector-to-
target contact, and lysis allowed to proceed at 37°C in 5% CO2
for 8 h. After incubation, 100 Al of supernatant from each assaywell was removed for measurement of "Cr release and calculation
of specific lysis above background .
Results and Discussion
The cell-cell adhesion assay measures the binding of nonad-
herent cells expressing transfected class I genes to monolayers
ofCHO cells that express high levels ofhuman CD8a . The
ability ofmouse class I and class Ib molecules to bind human
CD8a molecules in this assay is well established (2, 20). CIR,
the recipient humanB lymphoma cell line for the class I gene
constructs, lacks HLA-A and HLA-B genes, and expresses
only low levels ofHLA-C (11, 21) . Untransfected CIR cells
therefore do not bind well to CD8a-positiveCHO cells . CIR
cells can, however, express high levels of transfected class
I genes whose expression is controlled by their own or
heterologous promoters . Transfected CIR cell lines will ex-
press the introduced mouse or human class I heavy chains
along with human ß2-microglobulin . Staining with an anti-
human ß2-microglobulin mAb can therefore be used to
compare the level of total class I surface expression of cells
transfected with the different gene constructs . Fig . 1 shows
the cell surface staining profiles as analyzed in the flow cytom-
eter of four CIR B cell lines with the anti-human ß2-
microglobulin mAb BBM.1 . The level of expression of en-
dogenous class I molecules in mock transfected CIR cells is
very low . In contrast, the levels of ß2-microglobulin are
significantly higher than in the CIR parent, and roughly
equivalent for transfected cell lines that express HLA-A2.1,
TLA, or the LQ3 chimeric molecule . Staining with mAbs
specific for the various transfected class I heavy chains confirms
that the increased level of ß2-microglobuhn expression is due
to expression of the transfected genes (data not shown) . In
a separate experiment, similar results were obtained using a
CIR cell transfected with a gene encoding a chimeric
Ld/TLA gene (data not shown) . Because the levels of expres-
Figure 1 .
￿
Flow cytometric analysis ofCIRparent (a) and stable trans-
fectant (b-d) cell lines. Staining with the anti-human 02-microglobulin
mAb BBM.1 is shown (19) . The relative cell number (ordinate) is plotted
as a function of the log of the fluorescence intensity (abscissa) . Staining
for lineCIRTL .J (b), CIRLQ3 lineD (c), andCIRA2.1 (d) are shown .
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￿
Qa-2 Does Not Interact with CD8
sion of the different transfected genes are nearly equivalent
(Fig. 1), theCD8 binding ability ofeach line can be compared .
Fig. 2 depicts representative data on the binding of the
transfectedCIR cell lines to CD8a-positive and controlCHO
cell monolayers. The LQ3 transfectant lines A andD did not
bind detectably above background to the CD8oi-positive
monolayers . By contrast, the three cell lines expressingHLA-
A2.1, TLA, or Ld/TLA class I molecules bound well . Al-
though the CIR cells overexpress the transfected class I genes
and the CHO cells overexpress human CD8a, it could be
argued that a low but functional binding affinity is not de-
tected by the method employed . However, in the studies of
Salter et al . (12), there was complete concordance between
results from the binding assay and the ability oftransfectants
that express class I mutants to be recognized by primary, al-
loreactive CTLs . The binding data shown are also consistent
with our own prior functional studies, in that Ld/TLA can
serve as a target for primary, CD8-dependent CTLs while
LQ 3 cannot (2, 10) . Similar results were obtained in three
separate experiments in which the binding to CD8 positive
and negative monolayers were compared. The ratio of the
percent ofTLA andHLA-A2.1 positive control cells bound
to CD8 positive monolayers to the percent binding of these
cells to CD8 negative monolayers ranged from 2.0 to 5 .1.
In every case the difference in cells bound to CD8+ vs.
CD8 - CHO monolayers was statistically significant, with
p <0.001 by the Student's t test . In contrast, in two experi-
ments, the ratio of binding of LQ3 expressing CIR cells to
CD8+ and CD8 - CHO monolayers was 1.0 and 1.1, respec-
tively, and the difference in percent cellsbound was not statisti-
cally significant . In the third experiment, the ratio ofCD8+
Figure 2 .
￿
Cell-cell adhesion assay. Binding of radiolabeled CIR cells
to CD8a(-) and to human CD8a(+) adherent CHO cell monolayers
is depicted as the percentage of input CIR cells retained after extensive
washing, Mock transfected CIRparent (CIR), CIRA2.1(HLAA2), CIR
TL.J (TLA), Ld/TLA (L/TLA), and LQ3 lines A and D have been de-
scribed previously (2, 11) or are described in Fig. 1 and Materials and
Methods. CHO cell lines CHOA (hCD8[-]) and CHOA (hCD8[+])
have been previously described (11) . Error bars represent the SD of tripli-
cate samples . Representative data from one ofthree experiments is shown .to CD8 - binding by LQ3 cells was 1.9, 31.2% ± 3.0 (SE
of the mean) cells bound to CD8+ CHO monolayers vs.
16.8% ± 0.6 to CD8 - monolayers. However, in this ex-
periment the negative control CIR cells also bound better
to the CD8+ CHO monolayers, 21.8% ± 1.0 vs. 13.5%
± 0.7. The difference in binding to the CD8 monolayers
for both LQ3 and control CIR cells is statistically significant
(p <0.005) in both cases. It is therefore possible that this third
experiment was for some reason unusually sensitive, enabling
detection of binding by the low level of HLA-C expressed
by CIR cells to human CD8. Consistent with a possible en-
hanced sensitivity, in this same experiment the TLA and A2.1
expressing CIR cells gave the highest percent cells bound
that has been obtained in these assays, 81.8% and 67.4%,
respectively. In summary, the data indicate that LQ3 cannot
bind to human CD8 because in all cases the LQ3 transfec-
tant bound much less well to the CD8+ CHO cells than
did either the TLA or HLA-A2 transfectants, in all three
experiments LQ3 binding was similar to that of the CIR
parent negative control, and in two of three cases binding
of LQ3 cells to CD8+ and CD8 - CHO cells was equivalent.
Although the Qa-2 0 domain of LQ3 is incapable of
binding human CD8a/a homodimers, it may still be capable
of interacting with mouse CD8a/(3 heterodimers. To date,
there has been complete concordance in the ability of mouse
class 10 domains to interact with both human and mouse
CD8 (2, 11, 12, 22) . However, the data are not that exten-
sive, particularly for nonclassical class I molecules for which
only one example currently exists (2). In addition, recent work
by two independent groups indicates that the presence ofthe
mouse CD8a chain appears to both broaden the range and
strengthen the response of CD8-a3 domain interactions (23,
24). Therefore, in order to rule out the possibility that LQ3
could interact with mouse CD8a/(3 heterodimers expressed
at physiologic levels, a second assay was performed.
CTLs are capable of binding and initiating a degranula-
tion response to purified class I and class Ib MHC antigens
coated on a plate when they are first suboptimally activated
by preincubation with soluble anti-T cell receptor mAbs (22,
25). In the absence of mAb preincubation these functions
do not occur. Furthermore, both binding and degranulation
can be blocked with anti-CD8 mAbs (22). These observa-
tions suggest that, following T cell receptor activation with
fluid-phase antibodies, a second signal which can be medi-
ated through a CD8 interaction with an "irrelevant" class
I molecule is required to activate the CTL. This second signal
is also required for the initiationof polyphosphoinositide hy-
drolysis (25). In the present study, we modified this assay
by using CIR target cells that express equivalent levels of
transfected class I or class Ib genes (see Fig. 1) instead of
purified, plate-bound MHC antigens. By using two mouse
CTL clones that are Kb-specific, no influence from bound
peptides or the al and a2 domains of the transfected class
I gene is possible (26). Additionally, use of human cell line
targets should reduce the possibility ofother second signals,
aside from those delivered through otheradhesion molecules
(reviewed in reference 27), from activating the CTL. Finally,




cause it has been shown that human class I a3 domains are
deficient for interactions with mouse CD8 (28, 29).
Anti-Kb CTL lines C30 and C35 were made competent
for killing by preincubation with fluid-phase mAb 2C11just
before use. Target cells loaded with "Cr were incubated
with effectors at various ratios for 8 h and the amount released,
due to specific lysis abovebackground, was measured. When
either of the CTL clone lines were not made competent by
mAb preincubation, or when line C30 was preincubated with
the irrelevant mAb F23.1, the resultant "Cr release was very
low in all repeats ofthe assay (maximum 0.8% at an effector
to target ratioof 5:1, data not shown). However, specific lysis
of CIR transfectants expressing the Ld/TLA chimeric mol-
ecule is significantly abovethe background seen with the nega-
tive control transfectant A2.1 (Fig. 3). Background 51Cr re-
lease is consistently -10% in all 8-h assay repeats using
effector-to-target ratios of 20:1 down to 1.25:1. Previously
it was shown that the Ld/TLA chimeric molecule could
support a CD8-dependent alloantigenic response and this re-
activity could be blocked with anti-CD8 mAbs (2). The
Ld/TLA-mediated cytolysis is blocked by 21% and 32% at
effector-to-target ratios of 20:1 and 5 :1, respectively, with
a 10-Ag preincubation of anti-CD8a mAb (M. Teitell, un-
published data, not shown). Also, the low level of background
lysis due to CIR A2.1 transfectant targets was not affected
by effector clone preincubation with anti-CD8a mAb (data
not shown). This result further supports the proposed mech-
anism of CTL activation through CD8 interactions. Several
other CIR transfectants that express different class I mole-
cules are effective in this assay, including one molecule that
did not function in the cell-cell adhesion assay, and this cy-
tolysis also was partially blocked with anti-CD8a mAb prein-
cubation (M . Teitell, manuscript in preparation). In contrast,
Fig. 3 demonstrates that the chimeric LQ3 molecule is un-
able to activate a CTL response through CD8 interactions,
as the amount of "Cr released from loaded targets is equiva-












C138-mediated lysis of transfected CIR target cells. Theper-
cent cytolysis is calculated as (specific release - spontaneous release)/(total
release - spontaneous release) x 100 and depicted as a function of the
effector-to-target ratio. The figure shows thecytolysis ofcell lines expressing
equivalent levels ofHLA-A2.1 (A2.1), LQ3, and La/TLA (L/TLA) trans-
fected genes by mAb 2C11 preincubated CTL clone C30. These results
are identical to those obtained with CTL clone C35 and are reproducible
for effector-to-target ratios up to 20:1. Errorbars represent the SD ofthree
measurements.The LQ molecule might not bind human CD8 or permit
mouse CTL activation because the Ld al and a2 domains
could potentially distort or interfere with the normal con-
formation or accessibility of the Qa-2 0 domain. We con-
sider these possibilities unlikely because the Ld and Qa-2 a3
domains are highly similar in sequence. Furthermore, Qa-
2-specific CTLs also appear to be CD8 independent. In ad-
dition, results depicted in Fig. 3 and those of previous ex-
periments on the chimeric Ld molecule Ld/TLA support the
notion that 0 domain functions are not disturbed in chi-
meric molecules by the a1 and a2 domains (2). It also is
possible that the 0 domain in LQ3 is distorted by its associ-
ation with human 02-microglobulin in the CIR transfec-
tants and also, presumably, by bovine 02-microglobulin ob-
tained by exchange in the tissue culture medium. Although
not formally excluded, we consider these explanations un-
likely for the reasons outlined here. First, the behavior of in-
tact Qa-2 itself is at least consistent with an inability to in-
teract with CD8. Second, distortion of the LQ3 domain in
the presence of heterologous 02-microglobulin could not
also apply to Ld or Ld/TLA molecules despite the high de-
gree of sequence conservation. It should be noted that based
upon the structures of both human and mouse class I mole-
cules (30-32), all of the amino acids likely to be important
for interacting with 02-microglobulin in Kb, TLA, and
Qa-2 are conserved (Fig. 4) . We conclude therefore that the
most likely explanation is that Qa-2 does not interact with
either mouse or human CD8 and that those secondary CTLs
that recognize Ld but not LQ3, and which are not inhibitable
with anti-CD8 mAbs (10), probably still require a CD8 in-
teraction in order to become activated. It is still formally pos-
sible, however, that there is a second defect in the Qa-2 a3
domain in the LQ3 hybrid.
The Q7b a3 domain differs from the Ld a3 domain,
which does bind to CD8 (data not shown), by only six amino
acid substitutions and a three amino acid insertion at the car-
boxy terminus (33, 34; Fig. 4). Although it is not possible
to reach a definitive conclusion as to which of the changes
are critical for interfering with CD8 binding, the carboxy-
terminal three amino acid insertion at positions 275-277 is
perhaps responsible for the lack of CD8 interaction. The
H-2Dd 0 domain has a carboxy-terminal insertion of
Consensus
similar length (35), and it is presumed not to be altered in
its ability to interact with CD8. However, the Q7b 0 do-
main sequence contains a bulky tryptophan group at posi-
tion 277, which is not present in the H-2Dd a3 domain, and
this substitution could prevent 0 domain-CD8binding. Qa-2
molecules that span the plasma membrane, and which there-
fore are not phosphatidylinositol linked (36), could contain
this tryptophan group up to 10-15 amino acids external to
the plasma membrane. The K to Y and E to A substitutions,
at positions 196 and 198, respectively, may also effect a3 do-
main-CD8 interactions. Extrapolation of data from the crystal
structure suggests that these changes are found on an external
facing loop between the 0 domain 0-strands 1 and 2 (30-32),
and they replace two charged amino acids with two neutral
ones. However, positive, negative, and in some caseseven neu-
tral amino acids can occupy these positions in various class
I molecules that are presumed capable of CD8 binding. Among
the remaining substitutions that distinguish the Q7b and Ld
0 domains, the E to D and S to P alterations at positions
183 and 184 and the R to H change at position 260 are not
likely to have an important effect on CD8 binding. These
changes replace Ld amino acids with those found in both
TLA and the human consensus 0 domain sequences. Fi-
nally, the Y to N substitution at position 262 is potentially
important, but the human consensus 0 domain sequence
contains a glutamine at this position which is a rather con-
servative change from the asparagine in Q7b . Whichever
substitutions turn out to be critical, the data suggest that
a larger than expected area of the 0 domain may be involved
directly in CD8 interactions. Alternatively, the substituted
amino acids might disrupt the conformation or accessibility
of the previously defined minimal CD8 binding domain.
Analysis of transgenic mice that express LQ3 has shown
that this class I molecule does not function normally in ei-
ther positive or negative selection of the T cell repertoire (37).
The data presented here provide strong evidence that the de-
fect in LQ3 is indeed due to the loss of binding to CD8, and
therefore that effective CD8 interactions are required for posi-
tive and negative selection in the thymus. Our data on LQ3
is consistent with recent experiments showing that mutant
class I molecules, bearing 0 domain substitutions that dis-
rupt CD8 binding, cannot carry out either positive or nega-


































































Consensus sequence of the human class I a3 domain compared to Ld, TLA (encoded by T18d), and Qa-2 (encoded by Q'76) 0 domains.
Boxed areas in the consensus sequence represent human class 10 domain polymorphic amino acids as described in Parham et al. (45). The Ld sequence
was obtained from Linsk et al. (33), the TLA sequence was obtained from Fisher et al. (46), and the Qa-2 sequence was obtained from Devlin et
al. (34). Amino acids that differ between Ld, TLA, and Qa-2 and the consensus sequence are indicated. The six amino acids that differ between Ld
and Qa-2 are numbered, as is the three amino acid insert near the carboxy terminus of Qa-2. Arrows above the consensus sequence indicate the position
of Qa-2 variant residues, which are due to encoding of this class I molecule by different genes with the Qa locus (34). Underlined portions of the
sequence have been implicated in binding to CD8 (12).tive selection (38, 39). They arealso consistent with studies
demonstrating that human HLA class I molecules do not
carryout positive selectionin transgenic mice (28), probably
becausehumanclass I molecules do not bind to mouse CD8
(28, 29).
The Q7-encoded Qa-2 classIb molecule is unusual in sev-
eral respects. It is attached to theplasma membrane by aphos-
phatidylinositol linkage (36, 40), its expression as acell-bound
molecule is controlled in part by alternate splicing mecha-
nisms(41), andit can transmit an intracellular activation signal
when cross-linked by specific cell surface antibodies (42, 43).
Although, like LQ3, Qa-2 is probably incapable of binding
CD8, this does notimply that this molecule hasno significant









not exclude a possibility that it participates in negative or
positive selection. Some or all of thepreviously characterized
anti-Qa-2allogeneic CTLmayhave arisen as aresult ofpositive
selection of these T cells not on Qa-2, but on another class
Imolecule(s), most likely with CD8 binding capabilities. Re-
cently, however, Qa-2 hasbeen shown to bind endogenously
derived nonameric peptides (44; Joyce, S., P. Tabaczewski,
R. H. Angeletti, S. G. Nathenson, andI. Stroynowski.Manu-
script submitted for publication). Thus, it remains possible
that anti-Qa-2CTL, which aredirectly selected on Qa-2/pep-
tide complexes, originate from a novel and thus far not
identified developmental pathway that does not depend on
CD8 coreceptor.
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